Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On September 3, 2026, BIO-key International, Inc. (the "Company") convened its 2026 Annual Meeting of Stockholders (the "Annual Meeting"), which was adjourned and reconvened on Friday, October 2, 2026 and was adjourned and reconvened again on Friday, October 30, 2026, in each case at 10:00 a.m., local time, at the Company's offices at 101 Crawfords Corner Road, Suite 4116, Holmdel, NJ 07733. All holders of record of the Company's common stock outstanding as of the close of business on July 15, 2026 were entitled to vote at the Annual Meeting.

As previously reported in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on October 6, 2026, at the reconvened Annual Meeting held on October 2, 2026, the Company's stockholders approved Proposals 1, 2 and 3. At the reconvened Annual Meeting held on October 30, 2026, the Company's stockholders approved Proposal 4 as set forth below. Proposal 4 is more fully described in the Company's definitive proxy statement on Schedule 14A, filed with the SEC on July 24, 2026 (the "Proxy Statement"), and the supplement to the Proxy Statement filed with the SEC on August 24, 2026 (the "Supplement").

Proposal 4, which sought stockholder approval, for purposes of complying with Nasdaq Listing Rule 5635(d), of the issuance of up to 1,236,668 shares of the Company's common stock upon the exercise of warrants issued in the Company's August 10, 2026 warrant inducement transaction, was approved, and the final voting results were as follows:

No other matters were submitted to a vote at the reconvened Annual Meeting, and the Annual Meeting was concluded.